China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug
| LYFCX Fund | USD 13.35 0.04 0.30% |
Slightly above 54% of Alphacentric Lifesci's investor base is interested to short. The analysis of overall sentiment of trading Alphacentric Lifesci Healthcare mutual fund suggests that many investors are impartial at this time. Alphacentric Lifesci's investing sentiment can be driven by a variety of factors including economic data, Alphacentric Lifesci's earnings reports, geopolitical events, and overall market trends.
Alphacentric |
Lilly is aiming to strengthen its position as a leader in the obesity treatment market, which is expected to hit 150 billion in revenue by the next decade. Last year, the company spent about 2 billion to acquire Versanis drug that acts directly on fat cells, without prompting lean mass loss. Several other drugmakers including Regeneron and Scholar Rock are testing treatments that could help preserve muscle, which is often lost when patients lose weight through lifestyle changes, bariatric surgery or the use of GLP-1 treatments such as Lillys Zepbound and Novo Nordisks Wegovy.
Read at finance.yahoo.com
 |
Alphacentric Lifesci Fundamental Analysis
We analyze Alphacentric Lifesci's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alphacentric Lifesci using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alphacentric Lifesci based on its fundamental data. In general, a quantitative approach, as applied to this mutual fund, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Asset
Total Asset Comparative Analysis
Alphacentric Lifesci is currently under evaluation in total asset among similar funds. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Alphacentric Lifesci Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Alphacentric Lifesci mutual fund to make a market-neutral strategy. Peer analysis of Alphacentric Lifesci could also be used in its relative valuation, which is a method of valuing Alphacentric Lifesci by comparing valuation metrics with similar companies.
Peers
Alphacentric Lifesci Related Equities
Other Information on Investing in Alphacentric Mutual Fund
Alphacentric Lifesci financial ratios help investors to determine whether Alphacentric Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Alphacentric with respect to the benefits of owning Alphacentric Lifesci security.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |